It was suggested that the lack of complete success was due to the failure of the glycerol–saline technique to protect the corneal endothelium. It was therefore decided to investigate directly ...

Vyznova (neltependocel, formerly AURN001) is the world's first allogeneic cell therapy for corneal endothelial disease, according to the Seattle, Washington-based company. It already has ...

A 52-year-old woman with iridocorneal endothelial (ICE) syndrome, a genetic mutation affecting vision, successfully recovers ...

Deepinder Dhaliwal, MD, LAc, explores advancements in managing Fuchs endothelial corneal dystrophy, highlighting Descemet stripping only (DSO). Long-term outcomes show promising results, supporting ...

AURN001 is a combination cell therapy product candidate comprised of allogeneic human corneal endothelial cells (neltependocel) and a rho kinase inhibitor (Y-27632). AURN001 is intended to be ...

In 2022, doctors in Japan performed a transplant of iPS cell-derived corneal endothelial cells iPS cell derived-corneal endothelial cell transplants are injected and take about 20 minutes In Japan ...

The study enrolled 97 people in the U.S. and Canada with corneal edema secondary to endothelial dysfunction, a disease that can currently only be treated with invasive specialty surgery.

Ripasudil hydrochloride hydrate is under clinical development by Kowa and currently in Phase II for Retinopathy Of Prematurity.